Work

573 POSTER Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumors with mutated EGFR

Year: 2006

Type: article

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(06)70578-x

Authors: R. Plummer, L. Vidal, L. Li, H. Shaw, R. Perrett, M. Shahidi, A. Amelsberg, G. Temple, H. Calvert, J. de Bono

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2086665729

FWCI:

Cites:

Cited by: 4

Related to: 10